{
  "id": "643d41e757b1c7a315000037",
  "type": "list",
  "question": "What is the first indication for lurasidone?",
  "ideal_answer": "Lurasidone's initial indication is the treatment of bipolar depression.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26771990",
    "http://www.ncbi.nlm.nih.gov/pubmed/25852975",
    "http://www.ncbi.nlm.nih.gov/pubmed/26755968",
    "http://www.ncbi.nlm.nih.gov/pubmed/26316760",
    "http://www.ncbi.nlm.nih.gov/pubmed/24955752",
    "http://www.ncbi.nlm.nih.gov/pubmed/22146224",
    "http://www.ncbi.nlm.nih.gov/pubmed/22675261",
    "http://www.ncbi.nlm.nih.gov/pubmed/21177242",
    "http://www.ncbi.nlm.nih.gov/pubmed/34860899",
    "http://www.ncbi.nlm.nih.gov/pubmed/22364325",
    "http://www.ncbi.nlm.nih.gov/pubmed/33572131",
    "http://www.ncbi.nlm.nih.gov/pubmed/34534629",
    "http://www.ncbi.nlm.nih.gov/pubmed/25698146",
    "http://www.ncbi.nlm.nih.gov/pubmed/32124704",
    "http://www.ncbi.nlm.nih.gov/pubmed/29962579",
    "http://www.ncbi.nlm.nih.gov/pubmed/21446639"
  ],
  "snippets": [
    {
      "text": "Lurasidone is an atypical antipsychotic drug that was initially developed for the treatment of schizophrenia",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26771990",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "he Effectiveness of Lurasidone Add-On for Residual Aggressive Behavior and Obsessive Symptoms in Antipsychotic-Treated Children and Adolescents with Tourette Syndrome:",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33572131",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This article briefly reviews the novel atypical second-generation antipsychotic drugs iloperidone (Fanapt\u00ae), asenapine (Saphris\u00ae), and lurasidone (Latuda\u00ae), all of which have been approved by the U.S. Food and Drug Administration since 2009. Each is indicated for the treatment of schizophrenia, ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21446639",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lurasidone (Latuda(\u00ae)), a benzisothiazole derivative antipsychotic, is approved in the USA and Canada for the treatment of adults with major depressive episodes (MDE) associated with bipolar I disorder; this article reviews studies of lurasidone in this indication.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25698146",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lurasidone is an atypical antipsychotic drug that was initially developed for the treatment of schizophrenia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26771990",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lurasidone is a drug in the benzisothiazole class approved by the US Food and Drug Administration in June 2013 for the acute treatment of bipolar depression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26316760",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application Lurasidone (Latuda, Sunovion Pharmaceuticals), an atypical antipsychotic, for the treatment of schizophrenia in adolescents 13-17 years of age.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29962579",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lurasidone is one of several antipsychotics approved in the recent past by the US FDA for the treatment of schizophrenia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22364325",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lurasidone is a novel benzoisothiazol antipsychotic that has recently been approved for the treatment of schizophrenia in the U.S. Like many other second-generation antipsychotics, it has a high affinity for dopamine D(2) and serotonin 5-HT(2A) receptors as well as a high affinity for 5-HT(7) receptors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22146224",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the UK, and is also approved in the USA and Canada for the treatment of major depressive episodes associated with bipolar I disorder as either a monotherapy or adjunctive therapy with lithium or valproate.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26755968",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, lurasidone was approved to treat bipolar depression either as monotherapy or adjunctively with lithium or valproate.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852975",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lurasidone is a second-generation antipsychotic newly approved by the U.S. Food and Drug Administration for the treatment of schizophrenia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177242",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "cide risk. Lurasidone is an atypical antipsychotic agent indicated for the treatment of schizophrenia and for the treatment of major depressive episodes associated with bipolar ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955752",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Update on the development of lurasidone as a treatment for patients with acute schizophrenia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22675261",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Lurasidone: a new treatment option for schizophrenia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22146224",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Lurasidone is an important antipsychotic drug indicated for the treatment of schizophrenia and bipolar disorder, with an oral bioavailability of 9-19% owing to its poor aqueous solubility.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34534629",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background: Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia in 2010.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34860899",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lurasidone was approved by the United States Food and Drug Administration (FDA) for the treatment of schizophrenia, as well as for the treatment of bipolar depression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32124704",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "schizophrenia, Bipolar depression., Tourette syndrome"
}